Skip to main content
Equibles
ICCC logo

ICCC · Immucell Corp /De/ · Webcasts, Transcripts & Audio

Track ICCC — free

Use ICCC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ICCC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.75 +0.00 (+0.00%) At close · Oct 5
Rebalance outlook locked
Market Cap
$90.14M
Shares
9.08M
Volume · Oct 5 11.26K Avg daily vol (3M) 24.04K

Immucell Corp Webcasts

Earnings calls, investor updates, investor days and conferences for Immucell Corp (ICCC), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼6.9% $4.80M −$655,078 '22 Q3 22-10-05 ▼28.2% $3.91M −$1.67M '22 Q4 23-02-21 ▼42.6% $3.45M −$2.32M '23 Q1 23-04-05 ▼8.5% $3.53M −$1.38M '23 Q2 23-08-10 ▲12.5% $5.40M −$940,000 '23 Q3 23-10-05 ▲30.3% $5.10M −$1.14M '23 Q4 24-02-27 ▲110.6% $7.26M −$437,868 '24 Q1 24-04-09 ▲54.9% $5.47M −$1.53M '24 Q2 24-08-13 ▲11.4% $6.01M −$701,690 '24 Q3 24-11-13 ▲52.1% $7.75M $514,555 '24 Q4 25-01-10 ▲11.2% $8.07M $1.45M '25 Q1 25-05-14 ▲17.8% $6.44M $501,880 '25 Q2 25-07-09 ▼8.4% $5.51M −$139,748 '25 Q3 25-10-07 ▼1.6% $7.63M −$2.85M '25 Q4 26-02-26 ▲28.4% $10.36M $1.94M '26 Q1 26-05-15 LATEST ▲11.5% $7.19M $1.83M '26 Q2 26-08-14
Earnings call
FY26 · Q2
2026-08-14
Immucell Corp (ICCC) Q2 2026 Earnings Call Transcript
Confident tone Gross margin pressure Retain / Michigan State study Manufacturing capacity expansion
Revenue
$7.19M
▲ 11.5% YoY
Diluted EPS
$0.20
▲ 233.3% YoY
Gross margin
33.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-15
Immucell Corp (ICCC) Q1 2026 Earnings Call Transcript
Confident tone Revenue growth and First Quarter milestone Strategic focus on First Defense / Tri-Shield Manufacturing yield and capacity expansion
Revenue
$10.36M
▲ 28.4% YoY
Diluted EPS
$0.21
▲ 31.2% YoY
Gross margin
45.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Immucell Corp (ICCC) Q4 2025 Earnings Call
Confident tone First Defense franchise focus and strategy shift Re-Tain write-down and exit Gross margin improvement
Revenue
$7.63M*
▼ 1.6% YoY
Gross margin
38.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-07
Immucell Corp (ICCC) Q3 2025 Earnings Call Transcript
Confident tone Revenue and sales performance Financial turnaround and profitability First Defense product growth
Revenue
$5.51M
▼ 8.4% YoY
Diluted EPS
$-0.02
Gross margin
42.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-09
Immucell Corp (ICCC) Q2 2025 Earnings Call Transcript
Positive tone First Defense production capacity and recovery Re-Tain development and FDA pathway Colostrum inventory management
Revenue
$6.44M
▲ 17.8% YoY
Diluted EPS
$0.06
Gross margin
43.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Immucell Corp (ICCC) Q1 2025 Earnings Call Transcript
Confident tone First Defense sales growth and product suite Re-Tain investigational product use and FDA approval Gross margin improvement
Revenue
$8.07M
▲ 11.2% YoY
Diluted EPS
$0.16
Gross margin
41.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-10
Immucell Corp (ICCC) Q4 2024 Earnings Call Transcript
Confident tone Gross margin improvement Re-Tain FDA approval and commercial launch Contamination remediation and production yields
Revenue
$7.75M*
▲ 52.1% YoY
Gross margin
36.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Immucell Corp (ICCC) Q3 2024 Earnings Call Transcript
Positive tone Contamination remediation and production ramp First Defense sales and demand Gross margin recovery
Revenue
$6.01M
▲ 11.4% YoY
Diluted EPS
$-0.09
Gross margin
26.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Immucell Corp (ICCC) Q2 2024 Earnings Call Transcript
Positive tone Re-Tain FDA regulatory process Contamination events and remediation Gross margin pressure
Revenue
$5.47M
▲ 54.9% YoY
Diluted EPS
$-0.20
Gross margin
22.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-09
Immucell Corp (ICCC) Q1 2024 Earnings Call Transcript
Positive tone Gross Margin Improvement to Target Retain Regulatory Delays Record Sales Growth and Production Output
Revenue
$7.26M
▲ 110.6% YoY
Diluted EPS
$-0.06
Gross margin
31.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Immucell Corp (ICCC) Q4 2023 Earnings Call Transcript
Balanced tone Re-Tain FDA submission and approval timeline Contamination events and remediation Backlog and demand
Revenue
$5.10M*
▲ 30.3% YoY
Gross margin
24.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-05
Immucell Corp (ICCC) Q3 2023 Earnings Call Transcript
Revenue
$5.40M
▲ 12.5% YoY
Diluted EPS
$-0.12
Gross margin
23.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Immucell Corp (ICCC) Q2 2023 Earnings Call Transcript
Revenue
$3.53M
▼ 8.5% YoY
Diluted EPS
$-0.18
Gross margin
29.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-04-05
Immucell Corp (ICCC) Q1 2023 Earnings Call Transcript
Revenue
$3.45M
▼ 42.6% YoY
Diluted EPS
$-0.30
▼ 528.6% YoY
Gross margin
8.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-21
Immucell Corp (ICCC) Q4 2022 Earnings Call Transcript
Revenue
$3.91M*
▼ 28.2% YoY
Gross margin
25.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-10-05
Immucell Corp (ICCC) Q3 2022 Earnings Call Transcript
Revenue
$4.80M
▼ 6.9% YoY
Diluted EPS
$-0.08
▼ 500% YoY
Gross margin
38.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-07-07
Immucell Corp (ICCC) Q2 2022 Earnings Call Transcript
Revenue
$3.86M
▼ 15% YoY
Diluted EPS
$-0.09
▼ 550% YoY
Gross margin
44.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Immucell Corp (ICCC) Q1 2022 Earnings Call Transcript
Revenue
$6.00M
▲ 46.1% YoY
Diluted EPS
$0.07
Gross margin
51.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-22
Immucell Corp (ICCC) Q4 2021 Earnings Call Transcript
Revenue
$5.44M*
▲ 45.4% YoY
Gross margin
47.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-10-06
Immucell Corp (ICCC) Q3 2021 Earnings Call Transcript
Revenue
$5.15M
▲ 38.4% YoY
Diluted EPS
$0.02
Gross margin
47.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Immucell Corp (ICCC) Q2 2021 Earnings Call Transcript
Revenue
$4.54M
▲ 53.1% YoY
Diluted EPS
$0.02
Gross margin
45.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Immucell Corp (ICCC) Q1 2021 Earnings Call Transcript
Revenue
$4.11M
▼ 16.4% YoY
Diluted EPS
$-0.06
Gross margin
39.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-23
Immucell Corp (ICCC) Q4 2020 Earnings Call Transcript
Revenue
$3.74M*
▲ 3.1% YoY
Gross margin
43.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-12
Immucell Corp (ICCC) Q3 2020 Earnings Call Transcript
Revenue
$3.72M
▲ 25.3% YoY
Diluted EPS
$-0.04
Gross margin
46.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-07
Immucell Corp (ICCC) Q2 2020 Earnings Call Transcript
Revenue
$2.97M
▲ 9.4% YoY
Diluted EPS
$-0.11
Gross margin
43.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-13
Immucell Corp (ICCC) Q1 2020 Earnings Call Transcript
Revenue
$4.91M
▲ 11.3% YoY
Diluted EPS
$-0.02
▼ 166.7% YoY
Gross margin
45.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-18
Immucell Corp (ICCC) Q4 2019 Earnings Call
Revenue
$3.63M*
▲ 23.7% YoY
Gross margin
50.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 webcasts
Key facts CIK 811641 CUSIP 452525306 Visit website Investor relations